Actinium Forms Nuclear Medicine Focused Advisory Board to Facilitate Pipeline Clinical Development and Iomab-B Commercial Planning
July 17, 2018 17:30 ET | Actinium Pharmaceuticals
NEW YORK, July 17, 2018 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN:ATNM) ("Actinium" or "the Company"), today announced that it has appointed the members of its Nuclear...
Actinium to Host Webcast on July 10, 2018 to Discuss Actimab-A MRD clinical trial for Minimal Residual Disease in Postremission AML Patients
July 09, 2018 16:15 ET | Actinium Pharmaceuticals
Minimal Residual Disease is increasingly recognized as a primary driver of high AML relapse with a need for improved consolidation therapiesWebcast to be held on July 10, 2018 at 8:00 AM ET to discuss...
Actinium Announces New Clinical Trial to Study Effect of Actimab-A on Minimal Residual Disease in Postremission AML Patients
June 28, 2018 08:00 ET | Actinium Pharmaceuticals
Minimal Residual Disease is increasingly recognized as a primary driver of high AML relapse rate highlighting need for improved consolidation therapies Webcast to be held on July 10, 2018 at 8:00 AM...
Actinium Pharmaceuticals Announces Dosing of 38th Patient and 25 Percent Enrollment in Iomab-B Pivotal SIERRA Trial
June 26, 2018 08:00 ET | Actinium Pharmaceuticals
Iomab-B remains the only targeted conditioning treatment in clinical trials with the potential to increase access to and improve outcomes of bone marrow transplant              NEW YORK, June 26,...
Actinium Provides Update from Society of Nuclear Medicine and Molecular Imaging Annual Meeting
June 25, 2018 16:15 ET | Actinium Pharmaceuticals
Two Nuclear Medicine focused advisory boards have been formed to provide expertise and strategic guidance to Actinium  Meeting with Iomab-B and Actimab investigators to be held to provide trial...
Actinium Pharmaceuticals Announces Treatment of First Patient in Novel Combination Trial of Actimab-A Plus CLAG-M
June 13, 2018 08:00 ET | Actinium Pharmaceuticals
- Trial supports Actinium’s strategic expansion of its CD33 program into novel combinations that can lead to increased use of bone marrow transplants and expand the addressable patient population for...
Actinium Pharmaceuticals to Present at 19th Annual Bio€quity Europe Conference in Ghent, Belgium
May 08, 2018 07:30 ET | Actinium Pharmaceuticals
- Management to conduct business development and investor focused meetings at the conference NEW YORK, May 08, 2018 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN:ATNM)...
Actinium Pharmaceuticals Appoints Dr. Jeffrey Chell, Bone Marrow Transplant Visionary and Chief Executive Officer Emeritus of Be The Match and National Marrow Donor Program, to its Board of Directors
May 01, 2018 07:30 ET | Actinium Pharmaceuticals
Dr. Chell led Be the Match and the National Marrow Donor Program for 17 years establishing these organizations as the largest volunteer bone marrow transplant donor registry in the world that...
Actinium Pharmaceuticals Strengthens Targeted Myeloablation Focused Clinical Development Team with New Hires Including Experienced Bone Marrow Transplant Physician and Drug Developer Vijay Reddy, M.D., Ph.D. as Vice President, Clinical Development
April 18, 2018 07:30 ET | Actinium Pharmaceuticals
- Dr. Vijay Reddy joins Actinium with over 20 years of bone marrow transplant clinical experience including extensive product development experience at Pharmacyclics, an AbbVie Company, Medimmune and...
Actinium Pharmaceuticals to Showcase Capabilities of its AWE Technology Platform in Developing Biobetters at Upcoming AACR Annual Meeting
April 11, 2018 07:30 ET | Actinium Pharmaceuticals
- In vivo data to be presented via poster highlighting the ability of Actinium’s AWE Technology to yield increased cell killing power, survival benefit and a potential biobetter of daratumumab, a...